Barclays Issues Positive Forecast for Omnicell (NASDAQ:OMCL) Stock Price

Omnicell (NASDAQ:OMCL) had its price target lifted by analysts at Barclays from $39.00 to $58.00 in a research report issued on Thursday, Benzinga reports. The firm presently has an “equal weight” rating on the stock. Barclays‘s target price indicates a potential upside of 20.21% from the company’s current price.

OMCL has been the topic of several other research reports. Craig Hallum raised their price objective on shares of Omnicell from $45.00 to $64.00 and gave the company a “buy” rating in a research report on Thursday. Benchmark restated a “buy” rating and set a $48.00 price objective on shares of Omnicell in a research report on Wednesday, October 9th. StockNews.com upgraded shares of Omnicell from a “hold” rating to a “buy” rating in a research report on Saturday, October 19th. Wells Fargo & Company raised their price objective on shares of Omnicell from $30.00 to $41.00 and gave the company an “equal weight” rating in a research report on Monday, October 14th. Finally, Bank of America restated a “neutral” rating and set a $57.00 price objective (up previously from $44.00) on shares of Omnicell in a research report on Thursday. Five analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $49.14.

Omnicell Stock Performance

OMCL traded down $4.80 on Thursday, hitting $48.25. The company’s stock had a trading volume of 532,837 shares, compared to its average volume of 524,674. The company’s 50 day simple moving average is $43.14 and its 200-day simple moving average is $35.07. The firm has a market cap of $2.22 billion, a P/E ratio of -103.54, a price-to-earnings-growth ratio of 43.55 and a beta of 0.83. Omnicell has a 12 month low of $25.12 and a 12 month high of $55.74. The company has a quick ratio of 2.22, a current ratio of 2.45 and a debt-to-equity ratio of 0.47.

Omnicell (NASDAQ:OMCL) last posted its earnings results on Thursday, August 1st. The company reported $0.51 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.14 by $0.37. Omnicell had a negative net margin of 1.92% and a positive return on equity of 2.52%. The business had revenue of $276.80 million for the quarter, compared to analysts’ expectations of $254.41 million. During the same period in the prior year, the company posted $0.29 EPS. The business’s revenue for the quarter was down 7.4% compared to the same quarter last year. Analysts forecast that Omnicell will post 0.64 EPS for the current year.

Hedge Funds Weigh In On Omnicell

A number of large investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. raised its position in Omnicell by 1.4% in the 1st quarter. Vanguard Group Inc. now owns 5,651,732 shares of the company’s stock worth $165,200,000 after purchasing an additional 80,312 shares during the period. Pacer Advisors Inc. raised its position in Omnicell by 32.6% in the 2nd quarter. Pacer Advisors Inc. now owns 2,070,434 shares of the company’s stock worth $56,047,000 after purchasing an additional 508,789 shares during the period. Champlain Investment Partners LLC grew its holdings in Omnicell by 16.0% in the 1st quarter. Champlain Investment Partners LLC now owns 1,753,205 shares of the company’s stock worth $51,246,000 after acquiring an additional 241,235 shares during the last quarter. Dimensional Fund Advisors LP grew its holdings in Omnicell by 0.3% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,180,503 shares of the company’s stock worth $31,955,000 after acquiring an additional 3,570 shares during the last quarter. Finally, Federated Hermes Inc. grew its holdings in Omnicell by 1,113.6% in the 2nd quarter. Federated Hermes Inc. now owns 991,151 shares of the company’s stock worth $26,830,000 after acquiring an additional 909,480 shares during the last quarter. Hedge funds and other institutional investors own 97.70% of the company’s stock.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.